NEORAL
Total Payments
$77,477
Transactions
5
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $70,924 | 2 | 0 |
| 2020 | $6,484 | 2 | 0 |
| 2017 | $69.00 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77,408 | 4 | 99.9% |
| Food and Beverage | $69.00 | 1 | 0.1% |
Payments by Type
Research
$77,408
4 transactions
General
$69.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| I-SPY COVID TRIAL: AN ADAPTIVE PLATFORM TRIAL TO REDUCE MORTALITY AND VENTILATOR REQUIREMENTS FOR CRITICALLY ILL PATIENTS | Novartis Pharmaceuticals Corporation | $61,334 | 0 |
| RANDOMIZED PHASE IIA CLINICAL TRIAL OF CYCLOSPORINE FOR THE TREATMENT OF COVID-19(+) NON-ICU HOSPITAL INPATIENTS. | Novartis Pharmaceuticals Corporation | $9,590 | 0 |
| Randomized phase IIa clinical trial of cyclosporine for the treatment of COVID-19(+) non-ICU hospital inpatients. | Novartis Pharmaceuticals Corporation | $6,484 | 0 |
Top Doctors Receiving Payments for NEORAL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $77,408 | 4 |
| , M.D | Internal Medicine | Los Angeles, CA | $69.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $77,477
- Total Doctors 1
- Transactions 5
About NEORAL
NEORAL is a drug associated with $77,477 in payments to 1 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2021. In 2021, $70,924 was paid across 2 transactions to 0 doctors.
The most common payment nature for NEORAL is "Unspecified" ($77,408, 99.9% of total).
NEORAL is associated with 3 research studies, including "I-SPY COVID TRIAL: AN ADAPTIVE PLATFORM TRIAL TO REDUCE MORTALITY AND VENTILATOR REQUIREMENTS FOR CRITICALLY ILL PATIENTS" ($61,334).